It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can ...

This, Bernstein analysts said, “allows for faster, more efficient trials with higher chances of success.” Recruitment is ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital ...

U.S. equities surged in Friday’s midday trade as investor sentiment buoyed following Federal Reserve Chair Jerome Powell’s ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 88.

Tempus AI (TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81.25M.

Tempus is acquiring Paige for $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus' assumption of Paige's remaining commitment under its existing Microsoft Azure ...

Rising demand for precision and personalized medicine has significantly augmented the need for artificial intelligence ...

These stocks offer investors exposure to the booming AI market at reasonable valuations. Stock market indices are ...